Your session is about to expire
← Back to Search
MNA-D Patches for Cutaneous T-Cell Lymphoma (MNA-D Trial)
MNA-D Trial Summary
This trial is testing a new method of experimental treatment for CTCL, using small adhesive-like patches with very small micro-needles loaded with extremely low doses of doxorubicin. The goal is to test the safety and effectiveness of these patches, determine the best micro-dose of the drug, and evaluate the skin where the patches are applied.
MNA-D Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMNA-D Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MNA-D Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I currently have cancer.I have been diagnosed with CTCL based on a skin biopsy.I currently do not have any active infections.I am only using moisturizers for my skin cancer, no other treatments.I have an autoimmune disease or an active infection like HIV or hepatitis.I am not currently participating in any other clinical trials.I have enough skin patches or plaques for treatment application.I am willing to stop my current CTCL medications for the study.I am 18 or older and can understand the consent form.My cancer is in an early stage (IA or IB).I have pain that is not relieved by medication.
- Group 1: Micro needle array-Doxorubicin (MNA-D)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have other research studies explored the efficacy of Micro needle array-Doxorubicin (MNA-D)?
"Presently, the number of medical trials investigating Micro needle array-Doxorubicin (MNA-D) is 360 with 119 in Phase 3. While Providence, Rhode island holds many MNA-D studies, there are 23596 sites offering this medication worldwide."
How many individuals are eligible to participate in this medical research?
"Affirmative. As per the information on clinicaltrials.gov, this experiment is currently seeking participants; an initiative that was launched on March 9th 2016 and revised for the last time June 2nd 2022. 54 subjects need to be sought from a single medical facility."
Has the Federal Drug Administration sanctioned Micro needle array-Doxorubicin (MNA-D) for therapeutic purposes?
"As this is a Phase 1 trial, with limited data to support its efficacy and safety, the team at Power assessed MNA-D's risk profile as low (rating of 1)."
Does this trial represent a pioneering approach to research?
"To date, 360 clinical trials surrounding Micro needle array-Doxorubicin (MNA-D) are ongoing throughout 1941 cities in 66 countries. The first MNA-D study was launched by Alfacell and comprised of 300 participants back in 1997. Since then, 677 studies have been successfully concluded with the final phase 3 drug approval stage being reached for many of them."
Are there any vacancies left for participants in this research endeavor?
"Affirmative. Clinicaltrials.gov displays the fact that this research project, first advertised on March 9th 2016, is in its recruitment phase. 54 people are being sought out at a single site to participate in the trial."
To which diseases or conditions is Micro needle array-Doxorubicin (MNA-D) typically applied?
"Micro needle array-Doxorubicin (MNA-D) is a viable option for the treatment of lymphoma, hodgkins and other varieties of carcinomas such as bronchogenic or neuroblastoma. Additionally, MNA-D can be utilized to address Sezary Syndrome."
Share this study with friends
Copy Link
Messenger